Scarica l'app Stockscreener
7.06
5.11%
-0.38
Dopo l'orario di chiusura:
6.95
-0.11
-1.56%
Precedente Chiudi:
$7.44
Aprire:
$7.38
Volume 24 ore:
1.25M
Relative Volume:
0.43
Capitalizzazione di mercato:
$1.05B
Reddito:
$204.73M
Utile/perdita netta:
$-184.29M
Rapporto P/E:
-9.7703
EPS:
-0.7226
Flusso di cassa netto:
$-51.87M
1 W Prestazione:
-17.14%
1M Prestazione:
+8.12%
6M Prestazione:
+129.97%
1 anno Prestazione:
+121.32%
Intervallo 1D:
$6.95
$7.381
Intervallo di 1 settimana:
$6.95
$8.74
Portata 52W:
$2.545
$9.42
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Nome
Maravai Lifesciences Holdings Inc
Settore
Industria
Telefono
(858) 546-0004
Indirizzo
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
7.06 | 1.05B | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-05 | Iniziato | TD Cowen | Buy |
| 2025-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Iniziato | Guggenheim | Neutral |
| 2024-12-05 | Downgrade | Goldman | Neutral → Sell |
| 2024-11-14 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-08 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Iniziato | Craig Hallum | Buy |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-08-08 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Downgrade | Goldman | Buy → Neutral |
| 2023-01-05 | Downgrade | UBS | Buy → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-11-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2020-12-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Iniziato | Credit Suisse | Outperform |
| 2020-12-15 | Iniziato | Goldman | Buy |
| 2020-12-15 | Iniziato | Jefferies | Buy |
| 2020-12-15 | Iniziato | Robert W. Baird | Outperform |
| 2020-12-15 | Iniziato | Stifel | Buy |
| 2020-12-15 | Iniziato | William Blair | Outperform |
| 2020-12-14 | Iniziato | UBS | Buy |
Mostra tutto
Maravai Lifesciences Holdings Inc Borsa (MRVI) Ultime notizie
Millennium Management Reports 5.2% Stake in Maravai LifeSciences Holdings - kalkinemedia.com
More than 5% of Maravai LifeSciences (MRVI) shares are listed with shared voting power. - Stock Titan
Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal
Maravai Lifesciences CEO Brust Bernd Forfeits 29,250 Shares at $7.32 Each (NASDAQ: MRVI) - Kalkine Media
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com South Africa
MRVI Maintained by UBS -- Price Target Raised to $8.00 - GuruFocus
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com Nigeria
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com Canada
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com India
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com UK
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel (MRVI) - Seeking Alpha
Maravai (NASDAQ: MRVI) CFO now holds 423K shares after tax withholding - stocktitan.net
Maravai (MRVI) Technicals: Ends Up by 4.22% at $8.64 in Latest Trading - vinanet.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Why Maravai LifeSciences Holdings (MRVI) Stock Climbed After Its Latest Update - Sahm
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Maravai Lifesciences stock reaches 52-week high of 8.15 USD By Investing.com - Investing.com Nigeria
Maravai Lifesciences stock reaches 52-week high of 8.15 USD By Investing.com - Investing.com India
Maravai Lifesciences stock reaches 52-week high of 8.15 USD - investing.com
Maravai (MRVI) Earnings Reading: EPS Prints Above Forecast in the Latest Reading; Closing Move: The Market Price Advances 25.78% in Latest TradingPost-Announcement Reaction - vinanet.vn
Maravai Lifesciences Up Over 30%, on Pace for Largest Percent Increase in Over a Year -- Data Talk - Bitget
MRVI Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineNew Analyst Coverage - vinanet.vn
Maravai Lifesciences Earnings Call Highlights Margin Rebound - TipRanks
MRVI Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 54.65%Post-Announcement Reaction - vinanet.vn
Maravai LifeSciences (MRVI) Slides 1.38% to $5.70 as Key Support Level Comes into FocusALMA Signal - vinanet.vn
Wall Street Zen Upgrades Maravai LifeSciences (NASDAQ:MRVI) to Buy - MarketBeat
Maravai (MRVI) Q2 2026 Earnings Call Transcript - AOL.com
Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake - Stock Titan
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
Maravai (MRVI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Maravai Q2 2026 slides: margin expansion drives EBITDA guidance raise By Investing.com - Investing.com Nigeria
Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows - Quiver Quantitative
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Moomoo
Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - Yahoo Finance Singapore
MRVI Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $6.50 - GuruFocus
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - MarketBeat
Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platform - Bitget
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - marketscreener.com
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Yahoo Finance
Earnings call transcript: Maravai LifeSciences beats Q2 2026 estimates, shares fall - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation - DirectorsTalk Interviews
MRVI Looks 63.2% Overvalued on GF Value™ - GuruFocus
Is Maravai LifeSciences (MRVI) Overvalued After Q2 Earnings Miss? GF Score: 61/100 - GuruFocus
Maravai LifeSciences Q2 Earnings Call Highlights - Yahoo Finance
Maravai LifeSciences Q2 Earnings Call Highlights - TradingView
Maravai LifeSciences Holdings Inc (MRVI) (Q2 2026) Earnings Call - GuruFocus
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Inv - The National Law Review
Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - Yahoo Finance Australia
Maravai Lifesciences Holdings Inc Azioni (MRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maravai Lifesciences Holdings Inc Azioni (MRVI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORESHACK KURT | Officer |
Jun 10 '26 |
Proposed Sale |
5.10 |
25,000 |
127,500 |
0 |
| ORESHACK KURT | General Counsel |
Jun 09 '26 |
Sale |
5.06 |
25,000 |
126,500 |
360,767 |
| ORESHACK KURT | Officer |
Jun 09 '26 |
Proposed Sale |
5.06 |
25,000 |
126,500 |
0 |
| PRAHALAD MURALI | Former Director |
Dec 23 '25 |
Proposed Sale |
3.33 |
3,951 |
13,138 |
0 |
| Hopfield Jessica | Former Director |
Dec 19 '25 |
Proposed Sale |
3.48 |
53,951 |
187,526 |
0 |
| LUCIER GREGORY T | Director |
Dec 08 '25 |
Buy |
3.67 |
48,528 |
178,098 |
155,123 |
| LUCIER GREGORY T | Director |
Dec 05 '25 |
Buy |
3.70 |
51,472 |
190,446 |
106,595 |
| Brust Bernd | Chief Executive Officer |
Nov 13 '25 |
Buy |
3.25 |
216,212 |
702,689 |
466,771 |
| Brust Bernd | Chief Executive Officer |
Nov 12 '25 |
Buy |
3.21 |
93,358 |
299,679 |
250,559 |
| Brust Bernd | Chief Executive Officer |
Nov 11 '25 |
Buy |
3.24 |
157,201 |
509,331 |
157,201 |
0.12%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):